FDA Approves Carvykti (ciltacabtagene autoleucel) BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press/Media

Period	9 Mar 2022

Media coverage

Title	FDA Approves Carvykti (ciltacabtagene autoleucel) BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Media name/outlet	Drugs.com
Country/Territory	United States
Date	9/03/22
URL	https://www.drugs.com/newdrugs/fda-approves-carvykti-ciltacabtagene-autoleucel-bcma-directed-car-t-immunotherapy-patients-relapsed-5795.html
Persons	Sundar Jagannath